Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Mol Pharmacol ; 85(3): 510-9, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24368842

ABSTRACT

Considerable progress has been made in recent years in developing selective, potent monoacylglycerol lipase (MAGL) inhibitors. In the investigations of measures to inhibit this enzyme, less attention has been paid to improving our understanding of its catalytic mechanisms or substrate preferences. In our study, we used site-directed mutagenesis, and we show via versatile activity assays combined with molecular modeling that Cys242 and Tyr194, the two opposing amino acid residues in the catalytic cavity of MAGL, play important roles in determining the rate and the isomer preferences of monoacylglycerol hydrolysis. In contrast to wild-type enzymes that hydrolyzed 1- and 2-monoacylglycerols at similar rates, mutation of Cys242 to alanine caused a significant reduction in overall activity (maximal velocity, Vmax), particularly skewing the balanced hydrolysis of isomers to favor the 2-isomer. Molecular modeling studies indicate that this was caused by structural features unfavorable toward 1-isomers as well as impaired recognition of OH-groups in the glycerol moiety. Direct functional involvement of Cys242 in the catalysis was found unlikely due to the remote distance from the catalytic serine. Unlike C242A, mutation of Tyr194 did not bias the hydrolysis of 1- and 2-monoacylglycerols but significantly compromised overall activity. Finally, mutation of Cys242 was also found to impair inhibition of MAGL, especially that by fluorophosphonate derivatives (13- to 63-fold reduction in potency). Taken together, this study provides new experimental and modeling insights into the molecular mechanisms of MAGL-catalyzed hydrolysis of the primary endocannabinoid 2-arachidonoylglycerol and related monoacylglycerols.


Subject(s)
Cysteine/genetics , Enzyme Inhibitors/metabolism , Monoacylglycerol Lipases/genetics , Monoglycerides/metabolism , Arachidonic Acids/genetics , Arachidonic Acids/metabolism , Catalysis , Cell Line , Cysteine/metabolism , Endocannabinoids/genetics , Endocannabinoids/metabolism , Glycerides/genetics , Glycerides/metabolism , HEK293 Cells , Humans , Hydrolysis , Monoacylglycerol Lipases/metabolism , Monoglycerides/genetics , Mutation/genetics
2.
J Biol Chem ; 288(43): 31093-104, 2013 Oct 25.
Article in English | MEDLINE | ID: mdl-24014019

ABSTRACT

Monoacylglycerol lipases (MGLs) play an important role in lipid catabolism across all kingdoms of life by catalyzing the release of free fatty acids from monoacylglycerols. The three-dimensional structures of human and a bacterial MGL were determined only recently as the first members of this lipase family. In addition to the α/ß-hydrolase core, they showed unexpected structural similarities even in the cap region. Nevertheless, the structural basis for substrate binding and conformational changes of MGLs is poorly understood. Here, we present a comprehensive study of five crystal structures of MGL from Bacillus sp. H257 in its free form and in complex with different substrate analogs and the natural substrate 1-lauroylglycerol. The occurrence of different conformations reveals a high degree of conformational plasticity of the cap region. We identify a specific residue, Ile-145, that might act as a gatekeeper restricting access to the binding site. Site-directed mutagenesis of Ile-145 leads to significantly reduced hydrolase activity. Bacterial MGLs in complex with 1-lauroylglycerol, myristoyl, palmitoyl, and stearoyl substrate analogs enable identification of the binding sites for the alkyl chain and the glycerol moiety of the natural ligand. They also provide snapshots of the hydrolytic reaction of a bacterial MGL at different stages. The alkyl chains are buried in a hydrophobic tunnel in an extended conformation. Binding of the glycerol moiety is mediated via Glu-156 and water molecules. Analysis of the structural features responsible for cap plasticity and the binding modes of the ligands suggests conservation of these features also in human MGL.


Subject(s)
Bacillus/enzymology , Bacterial Proteins/chemistry , Monoacylglycerol Lipases/chemistry , Monoglycerides/chemistry , Bacillus/genetics , Bacterial Proteins/genetics , Crystallography, X-Ray , Humans , Hydrolysis , Monoacylglycerol Lipases/genetics , Monoglycerides/genetics , Mutagenesis, Site-Directed , Protein Structure, Tertiary , Structure-Activity Relationship , Substrate Specificity
3.
J Lipid Res ; 54(6): 1691-1697, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23564732

ABSTRACT

Bis(monoacylglycero)phosphate (BMP) assists lysosomal function by facilitating interaction of hydrolases and activator proteins with sphingolipid substrates. Impaired lysosomal degradation of the sphingolipid glucosylceramide (GC) occurs in Gaucher disease due to an inherited deficiency of acid ß-glucosidase, with secondary BMP alterations. We investigated the nature of BMP accumulation and whether its correction reduced the storage burden in a THP-1 macrophage model of Gaucher disease. Using sucrose gradients and detergent solubility, 98% of BMP resided in the detergent-soluble membranes (DSM) rather than in the detergent-resistant membranes (DRM) where 73% of GC predominated. There was a 2-fold widespread elevation in BMP, including the saturated, mono- and polyunsaturated species. Linoleic acid in the culture media selectively reduced BMP from 4.2 nmol/mg to 0.49 nmol/mg (except 18:1/18:2) and prevented up to one third of GC, dihexosylceramide (DHC), and trihexosylceramide (THC) from accumulating. The 2-fold reduction in these sphingolipids occurred only in the DRM and did not reduce 18:1/16:0. However, once GC had accumulated, linoleic acid could not reverse it, DHC, or THC, despite effectively reducing BMP. These results imply a causative link for BMP in the pathobiology of Gaucher disease and demonstrate that linoleic acid can shield the cell from excessive substrate accumulation.


Subject(s)
Gaucher Disease/metabolism , Lysophospholipids/metabolism , Lysosomes/metabolism , Macrophages/metabolism , Models, Biological , Monoglycerides/metabolism , Cell Line, Tumor , Ceramides/genetics , Ceramides/metabolism , Gaucher Disease/genetics , Gaucher Disease/pathology , Glucosylceramidase/genetics , Glucosylceramidase/metabolism , Humans , Linoleic Acid/genetics , Linoleic Acid/metabolism , Lysophospholipids/genetics , Lysosomes/pathology , Macrophages/pathology , Monoglycerides/genetics , Sphingolipids/genetics , Sphingolipids/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL